Table 2.

 Claims made about trastuzumab

Claim	n/218	Percentage (95% CI)	Kappa
Clinical Effectiveness
Trastuzumab confers clinical benefit(s)	166	76.1 (70.5–81.8)	0.94
There is uncertainty about clinical benefit(s)	13	6.0 (2.8–9.1)	0.87
Trastuzumab causes clinical harm(s)	11	5.0 (2.1–8.0)	0.95
There is uncertainty about clinical harm(s)	9	4.1 (1.5–6.8)	0.71
Cost, opportunity cost and comparative reimbursement systems
Trastuzumab is expensive	114	52.3 (45.7–58.9)	0.97
There would be an opportunity cost to funding trastuzumab	9	4.1 (1.5–6.8)	0.75
Not funding trastuzumab is the opportunity cost of waste/treating the unworthy	6	2.8 (0.6–4.9)	0.60
Private and foreign insurance systems fund trastuzumab	16	7.3 (3.9–10.8)	0.83
Private and foreign insurance systems may not fund trastuzumab	5	2.3 (0.3–4.3)	1.00
Rights
Access to trastuzumab is a right	25	11.5 (7.2–15.7)	0.98
Access to trastuzumab is not a right	2	0.9 (−0.3–2.2)	1.00